More than L2b in rectal lymphogranuloma venereum We declare no competing interests. The hospital's ethical committee approved the study protocol under number 201723. This study has been partly supported by Universidad de Buenos Aires grant UBACyT 20020150100223BA. ACE and KAB contributed equally. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. KAB, ACE, LLR, LSL, and MRF verified the data.
Background Chlamydia trachomatis (CT) can infect the anorectum producing various signs and symptoms. There is scarce literature regarding the differences between LGV and non-LGV CT anorectal manifestations. We compare the clinical spectrum of LGV and non-LGV infections. Methods Patients over 18 years with presumptive infectious anorectal symptoms were examined in two healthcare centres in Buenos Aires. The patients were studied and treated according to current sexually transmitted infection guidelines. Anorectal swabs were collected to detect and genotype CT. Results A three-year-long study on 317 patients with anorectal symptoms showed 45.11% CT infection (85% LGV strains). Of 140 samples, 92 were sequenced: 80/119 LGV (L2b 45%, L1 32.5% and L2 22.5%) and 12/21 non-LGV. Older age and HIV+ status were significantly higher in the LGV group. Anal discharge, bleeding, severe proctitis and anal ulcers were more common in the LGV group. Multivariate logistic regression analysis revealed that HIV infection, anorectal bleeding and oro-anal sex are independent predictors of LGV infection. Conclusions In patients with anorectal symptoms, LGV serovars predominate over non-LGV ones. Clinical manifestations are not pathognomonic of a specific biovar. If genotyping is not available, having clinical predictors may help to presume an LGV infection and define length of treatment.
Introducción: Las infecciones de transmisión sexual (ITS) afectan anualmente a millones de personas. La sífilis aumenta tanto a nivel mundial como nacional. El sexo anorreceptivo es factor predisponente y hombres que tienen sexo con hombres (HSH) son vulnerables. Las lesiones anales en estadio primario provocan intensa proctalgia y en estadio secundario pueden simular condilomas virales, que si resuelven espontáneamente quedan sin diagnóstico etiológico. Métodos: Estudio descriptivo, ambispectivo, transversal. Revisión de registros de pacientes atendidos en coloproctología del Hospital Fernández (01/01/2015 - 01/03/2019). Se incluyeron pacientes con serología confirmatoria. Variables analizadas: sexo, edad, diagnóstico de derivación, HIV, otras ITS, sexo anal/oro-anal, estadio, clínica y casos/año. Resultados: Setenta y siete casos (61 hombres, 12 mujeres, 4 mujeres trans). Edad mediana: 30 años (rango: 18 - 72), 48% <30 años, 83% no utilizó preservativo (100% de los HIV+). Diecisiete casos (22%) detectados durante pesquisa de Chlamydia. Cincuenta y ocho pacientes (75%) presentaron ITS asociada. Coexistieron sífilis, HIV y linfogranuloma venéreo (LGV) en 8 HSH. Manifestaciones observadas: proctalgia (77%), proctorragia (55%), secreción (53%) y úlcera anal (51%). 50% de mujeres llegaron con diagnóstico erróneo. Casos/año: 6 en 2015, 13 en 2016, 21 en 2017, 31 en 2018 y 6 en primer bimestre de 2019. Conclusiones: Se detectó aumento progresivo de casos de sífilis anorrectal (mayormente en HSH), que aun siendo HIV+ no usa preservativo. Actualmente debe sospecharse asociación de sífilis con LGV en HSH HIV+. La similitud clínica con patologías no venéreas y la remisión espontánea de lesiones obliga a testearla para evitar su progresión y cortar la cadena de contactos.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.